Prevalence of Obstructive Sleep Apnea-Hypopnea Syndrome in Patients with Acute Cerebral Infarction (P1.179)

Introduction: Obstructive sleep apnea-hypopnea syndrome (OSA) in patients with acute stroke is associated with prolonged hospitalization, poor functional outcome and higher stroke recurrence. Prevalence of OSA in this population is high (80[percnt]). The identification of predictors of OSA severity in early stage of stroke could be useful for prevention and treatment of cerebral infarction. Objective: To evaluate prevalence and severity of OSA in acute stroke patients, describe their clinical features and identify associated factors with OSA severity. Methods: 45 consecutive patients with cerebral infarction admitted to our hospital were analyzed. Polysomnography was performed in all patients within 10 days after stroke onset. Three patients were excluded because insufficient data for analysis. Patients were classified in 2 groups according to their apnea-hypopnea index (AHI): normal/mild OSA (AHI: l for comparison between groups, T test and χ² was used as appropriate. A p: <0.05 was considered statistically significant. Results: 42 patients, 27 (64.28[percnt]) males, mean age: 70.12 (SEM +1.89) years. Moderate-severe OSA (MSOSA) was diagnosed in 29 (69.04[percnt]). Comparison between MSOSA patients with those without MSOSA did not reveal any significant difference regarding the following factors: blood pressure at admission, dyslipidemia, atrial fibrillation, diabetes, prior stroke/myocardial infarction, smoking, NIHSS and TOAST classification. Significant statistical difference was found in body mass index: mean 29.96 vs 26.20 (p:0.014), mean weight (kg): 87.28 vs 75.08 (p:0.033), hospitalization length (days): mean 13.24 vs 6.08 (p:0.008). Conclusions: High prevalence of MSOSA was found in our population. Those patients had extended hospital stay, higher BMI and greater weight. Prolonged hospitalization was not related to greater NIHSS. Our results suggest that patients with acute cerebral infarction should be systematically assessed for the presence of OSA. Disclosure: Dr. Quiroga has nothing to disclose. Dr. Berrozpe has nothing to disclose. Dr. Chertcoff has nothing to disclose. Dr. Pantiu has nothing to disclose. Dr. Pacha has nothing to disclose. Dr. Leon Cejas has nothing to disclose. Dr. Martinez has nothing to disclose. Dr. Bonardo has nothing to disclose. Dr. Uribe Roca has nothing to disclose. Dr. Fernandez Pardal has nothing to disclose. Dr. Reisin has received personal compensation for activities with Shire HGT. Dr. Valiensi has nothing to disclose.